Trial Profile
A Phase 2 clinical study to investigate the potential of Betalutin combined with rituximab in 2nd line Follicular Lymphoma.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 31 May 2017
Price :
$35
*
At a glance
- Drugs Lutetium-177 lilotomab satetraxetan (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 31 May 2017 New trial record
- 24 May 2017 According to a Nordic Nanovector media release, this clinical trial is expected to begin in second half of 2017.